"Klinické centrum ISCARE a.s.. poskytuje specializované lékařské výkony již od roku 1995. Najdete u nás centrum reprodukční medicíny, klinické a výzkumné centrum pro střevní záněty, centrum jednodenní chirurgie, centrum ortopedie, centrum revmatologie, centrum andrologie a centrum žilní chirurgie."

During the past decade, ISCARE IVF a.s. conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "ISCARE IVF a.s." are "In Vitro Fertilisation (IVF) Treatment" (2 trials), "Infertility" (1 trials) and "Infertility, Female" (1 trials). Many other conditions were trialed in "ISCARE IVF a.s." in a lesser frequency.

Most popular intervention types in "ISCARE IVF a.s." are "Drug" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Barusiban" (2 trials), "Atosiban" (1 trials), "Degarelix mid-luteal, 2.5 mg" (1 trials) and "Highly purified menotrophin" (1 trials). Other intervention names were less common.

The vast majority of trials in "ISCARE IVF a.s." are 4 trials for "Female" genders.

Currently, there are NaN active trials in "ISCARE IVF a.s.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in ISCARE IVF a.s., undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ISCARE IVF a.s., 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".